I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450, ON THE DATE INDICATED BELOW.

Leleue Glahal Date: March 25 BY:

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Patent Application of:

Frederick H. Hausheer

Conf. No.: 3276

Group Art Unit:

1614

Appln. No.:

10/002,526

Examiner:

Phyllis G. Spivack

Filing Date:

October 26, 2001

: Attorney Docket No.: 066131-30US (X-0211)

Title:

METHOD FOR TREATING PATIENTS FOR RADIATION EXPOSURE

## REVOCATION AND APPOINTMENT OF ATTORNEY BY ASSIGNEE

The undersigned states that he is authorized to sign the document on behalf of the assignee of the above application, that the evidentiary documents relating to the assignment of the above application have been reviewed, and he certifies that, to the best of assignee's knowledge and belief, title to the above application is in assignee by virtue of an assignment recorded in the U.S. Patent and Trademark Office on October 26, 2001 under Reel 012354, Frame 0874.

BioNumerik Pharmaceuticals, Inc., assignee of the above application, by its undersigned representative, hereby revokes all previous Powers of Attorney and appoints the registered attorneys and agents associated with Customer No. 000570, Akin Gump Strauss Hauer & Feld LLP, as its attorneys or agents with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

Please address all correspondence to Customer No. 000570, namely, AKIN GUMP STRAUSS HAUER & FELD LLP, One Commerce Square, 2005 Market Street, Suite 2200, Philadelphia, Pennsylvania 19103-7013. Please direct all communications and telephone calls to Alan S. Nadel at 215-965-1280 (telephone) or 215-965-1210 (facsimile).

Respectfully submitted, BioNumerik Pharmaceuticals, Inc.

December 22, 2004 By:	<u> </u>
-----------------------	----------

Date Frederick H. Hausheer, M.D. Chief Executive Officer